<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01853722</url>
  </required_header>
  <id_info>
    <org_study_id>13-150-0002</org_study_id>
    <nct_id>NCT01853722</nct_id>
  </id_info>
  <brief_title>A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers</brief_title>
  <official_title>A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deacon Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Deacon Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proof-of-concept study evaluates the clinical efficacy and safety of DCN01 in prepping
      of the periocular region.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in periocular region bacterial load</measure>
    <time_frame>Baseline to 10 min post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of periocular regions with a reduction from baseline in bacterial load.</measure>
    <time_frame>Baseline to 10 min post dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events (reported, elicited, observed)</measure>
    <time_frame>Post dose and up to 2 weeks after (Day 1-14)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Ocular Infection</condition>
  <arm_group>
    <arm_group_label>DCN01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Unisol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCN01</intervention_name>
    <description>Three serial applications per periocular region.</description>
    <arm_group_label>DCN01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unisol</intervention_name>
    <description>Three serial applications per periocular region.</description>
    <arm_group_label>Unisol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have given a written, informed consent

          -  Be willing and able to follow all instructions

          -  A negative urine pregnancy test if female of childbearing potential

        Exclusion Criteria:

          -  Known sensitivities to study medication or its components

          -  Any signs of an active infection

          -  Use of disallowed products during the period indicated prior to the enrollment or
             during the study

          -  Be currently pregnant, nursing, or planning a pregnancy; or be a woman that has a
             positive pregnancy test

          -  Have a condition or a situation which, in the Investigator's opinion, may put the
             subject at increased risk, confound study data, or interfere significantly with the
             subject's study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <disposition_first_submitted>January 19, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>January 19, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 11, 2016</disposition_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DCN01</keyword>
  <keyword>Ocular Surgical Preparation</keyword>
  <keyword>Prophylaxis against infection</keyword>
  <keyword>Pre-operative prep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

